0001564590-20-019956.txt : 20200430 0001564590-20-019956.hdr.sgml : 20200430 20200430073806 ACCESSION NUMBER: 0001564590-20-019956 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200430 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200430 DATE AS OF CHANGE: 20200430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABIOMED INC CENTRAL INDEX KEY: 0000815094 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042743260 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09585 FILM NUMBER: 20833171 BUSINESS ADDRESS: STREET 1: 22 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 8-K 1 abmd-8k_20200430.htm 8-K abmd-8k_20200430.htm
false 0000815094 0000815094 2020-04-30 2020-04-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2020

 

ABIOMED, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-09585

04-2743260

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

22 Cherry Hill Drive
Danvers, Massachusetts 01923

(Address of Principal Executive Offices, including Zip Code)

(978) 646-1400

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, $0.01 par value

ABMD

The NASDAQ Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ 

 

 

 

Item 2.02   Results of Operations and Financial Condition.

 

On April 30, 2020, ABIOMED, Inc. (the “Company,” “we” or “us”) issued a press release reporting our financial results for our fourth quarter ended March 31, 2020. A copy of the press release is set forth as Exhibit 99.1 and is incorporated herein by reference. The information contained in this report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

 

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Reduction in Base Salary of Executive Officers

 

In April 2020, the Company announced that, in light of the disruption and uncertainty created by the evolving COVID-19 pandemic and its anticipated impact on the Company’s operations, all of its named and other executive officers, including the Company’s Chief Executive Officer, Chief Financial Officer, will be taking a temporary reduction in cash base salary through June 30, 2020. The Company’s Chief Executive Officer, Michael R. Minogue and its Chief Operating Officer, David Weber, will completely forgo their base salary, other than payments necessary to retain their benefits, resulting in a complete reduction in cash base salary for the remainder of the quarter. The Company’s Chief Financial Officer, Todd A. Trapp, and each of its other named executive officers will be taking a 50 percent reduction in cash base salary for the remainder of the quarter. These reductions in pay for the Company’s named executive officers are expected to last through June 30, 2020.

 

Reduction in Annual Cash Retainer for the Company’s Board of Directors

 

In April 2020, the Company announced that, in light of the disruption and uncertainty created by the evolving COVID-19 pandemic and its anticipated impact on the Company’s operations, the Board of Directors of the Company (the “Board”) determined that the annual cash retainer for each non-employee director serving on the Board or its committees will be temporarily reduced to 50 percent of the previously approved amount through June 30, 2020.  In the event that a non-employee director elected to receive equity in lieu of the annual cash retainer, as permitted under the Company’s non-employee director compensation program, such grant will occur in the ordinary course but will be reduced in value by 50 percent.

 

Item 7.01      Regulation FD Disclosure.

 

Acquisition of Breethe, Inc.

 

On April 24, 2020, the Company entered into a share purchase agreement with Breethe, Inc. (“Breethe”) providing for the acquisition of all of the issued shares of Breethe, a Maryland corporation. Breethe is engaged in research and development of a novel extracorporeal membrane oxygenation (ECMO) system that the Company expects will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including some patients suffering from cardiogenic shock, H1N1, or COVID-19. ECMO has also been utilized as a primary method of oxygenation and hemodynamic support for pediatric patients. Breethe has applied for 510k clearance by the Food and Drug Association (FDA). Terms of the acquisition are not being disclosed at this time.

 

Caution Concerning Forward-Looking Statements

 

This Form 8-K contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such statements include, but are not limited to, those regarding our financial performance and the impact of the COVID-19 pandemic on our operations and financial results and are subject to, among other risks, the COVID-19 pandemic and any related policies and actions by governments or other third parties. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.

The information contained in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed

incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

  

Description

99.1

  

Press release dated April 30, 2020

 

Exhibit Index

 

Exhibit

  

Description

99.1

  

Press release dated April 30, 2020

 

 

 

104

 

Cover Page Interactive Data File (embedded with the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

ABIOMED, Inc.

 

 

 

 

 

 

 

 

By:

 

/s/ Todd A. Trapp

 

 

 

 

 

 

Todd A. Trapp

Vice President and Chief Financial Officer

(Authorized Signatory)

Date: April 30, 2020

 

 

 

 

 

 

 

 EX-99.1 2 abmd-ex991_6.htm EX-99.1 abmd-ex991_6.htm

Exhibit 99.1

 

ABIOMED ANNOUNCES Q4 FY 2020 REVENUE OF $207 MILLION AND 28.1% OPERATING MARGIN

 

FY 2020 Annual Revenue of $841 Million, Up 9%, and 29.6% Operating Margin

 

DANVERS, Mass. — April 30, 2020 – Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported fourth quarter fiscal 2020 revenue of $206.7 million compared to revenue of $207.1 million for the same period of fiscal 2019. For fiscal year 2020, total revenue was $840.9 million, up 9% compared to revenue of $769.4 million, and operating income was $249.2 million, up 10.9% compared to operating income of $224.8 million in fiscal year 2019.

 

Recent financial and operating highlights include:

 

•

Worldwide Impella® heart pump revenue for the quarter totaled $197.4 million, a decrease of 1% compared to revenue of $199.5 million during the same period of the prior fiscal year. Worldwide Impella heart pump revenue was impacted by lower patient utilization due to the negative impact of two misleading publications in print within the quarter, primarily in US and Germany. The Company was beginning to see positive momentum in March based on our actions to educate the medical community on Impella FDA studies and new publications. In the second half of March, the COVID-19 pandemic drastically impacted patient utilization. Within the quarter, the company estimates COVID-19 had approximately a $17 million negative impact on revenue. Full year worldwide Impella heart pump revenue totaled $806.8 million for fiscal 2020, an increase of 9% compared to revenue of $741.7 million for the prior fiscal year.

 

•

U.S. Impella product revenue for the quarter totaled $164.0 million, a decrease of 3% compared to revenue of $169.7 million during the same period of the prior fiscal year with U.S. patient usage of the Impella heart pumps down 5% due primarily to the impact of COVID-19. Within the quarter, the company estimates COVID-19 had approximately a $15 million negative impact on U.S. Impella product revenue. Full year U.S. Impella revenue totaled $674.4 million, up 5% compared to $639.3 million in the prior fiscal year with U.S. patient usage of the Impella heart pumps up 6%.

 

•

Outside the U.S., Impella product revenue for the quarter totaled $33.4 million, an increase of 12% compared to revenue of $29.8 million during the same period of the prior fiscal year. Outside the U.S. revenue, specifically Europe, was negatively impacted by COVID-19 in the quarter. Full year Impella product revenue outside the U.S. totaled $132.4 million, an increase of 29% compared to $102.4 million in the prior fiscal year. Specifically, Japan revenue was $8.4 million for the quarter and $35.2 million for the year, up 55% and 101%, respectively, compared to prior fiscal year.

 

•

Gross margin for the fourth quarter of fiscal 2020 was 80.9% compared to 83.2% during the same period of fiscal 2019. For the full fiscal year 2020, gross margin was 82.0% compared to 83.2% in fiscal year 2019.

 

•

Operating income for the fourth quarter fiscal 2020 was $58.1 million, or 28.1% operating margin, compared to $65.4 million, or 31.6% operating margin in the same period of fiscal 2019. For the full fiscal year 2020, operating income was $249.2 million, or 29.6% of revenue, compared to $224.8 million, or 29.2% of revenue in the prior fiscal year.

 

•

Fourth quarter fiscal 2020 GAAP net income was $31.8 million, or $0.70 per diluted share, which includes a $13.6 million, or $0.30 per diluted share, unrealized loss on our investment in Shockwave. This compared to GAAP net income of $74.0 million or $1.60 per diluted share for the prior fiscal year, which benefited from a $23.6 million, or $0.51 per share, unrealized gain on our investment in Shockwave.

 

•

Full fiscal year 2020 GAAP net income was $203.0 million, or $4.43 per diluted share, which benefited from $14.8 million, or $0.32 per diluted share, of excess tax benefits related to employee share-based compensation awards recorded as a reduction of income tax expense. This compared to GAAP net income of $259.0 million or $5.61 per diluted share for the prior fiscal year, which benefited from $69.3 million, or $1.50 per diluted share, of excess tax benefits related to employee share-based compensation awards recorded as a reduction of income tax expense and a $23.6 million, or $0.51 per diluted share, unrealized gain on our investment in Shockwave.

 

•

The company generated operating cash flow of $86.6 million in the fourth quarter and $314.9 million for the full fiscal year 2020. As of March 31, 2020, the company had $650.9 million of cash and marketable securities and no debt.

 

•

The study, by Al-khadra, et al., published in the February 15, 2020 print edition of Catheterization & Cardiovascular Interventions.  The study of 21,848 non-emergent, high-risk patients who underwent percutaneous coronary intervention (PCI) with percutaneous ventricular assist devices (PVADs), including Impella, demonstrates the PVAD patients had a lower rate of mortality (6.1% vs. 8.8%, p= <.001), lower vascular complications (4.3% vs. 7.5%, p= .046), lower cardiac complications (5.6% vs. 14.5%, p= <.001),  lower respiratory complications (3.8% vs. 9.8%, p= <.001) and a similar rate of bleeding (2.7% vs. 2.8%, p= .581) than patients who underwent PCI with intra-aortic balloon pumps (IABPs). This publication also noted that PVAD patients had a shorter length of stay than IABP patients (4 days vs. 5 days p= <.001).

 

•

On March 25, the company announced numerous steps taken to aid the global medical community and contribute to improved patient care during the COVID-19 outbreak. During these challenging times, Abiomed has focused our Patients First mission on three guiding priorities: clinically supporting patients and physicians on-site, on-call and online, manufacturing and supplying Impella heart pumps to hospitals and keeping our employees and their families healthy and safe. The company has also donated more than 100,000 masks and other PPE equipment to hospitals in the U.S., Europe and Japan in need and will continue to do so as the COVID-19 pandemic continues.

 

•

On April 29, the company announced the acquisition of Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including patients suffering from cardiogenic shock, cardiac arrest or respiratory failure such as due to ARDS, H1N1, SARS, or COVID-19. Additionally, ECMO has also been utilized as a primary method of oxygenation and hemodynamic support for pediatric patients. Breethe has applied for 510k clearance by the Food and Drug Association (FDA). Terms of the acquisition are not being disclosed at this time.

 

•

The company is taking proactive actions to mitigate the business impact of COVID-19 to better match expenses to revenue in Q1. These actions taken include a hold on hiring, eliminating non-critical consultants, contractors, and temporary workers, reducing discretionary spending and implementing alternate work schedules for the Aachen and Danvers production teams. The CEO and COO have reduced their salaries by 100%, VPs and directors have reduced their salaries by 50% and 20% respectively for the first quarter. The Board of Directors have also reduced their cash retainers by 50% for Q1. Non-director employees at Massachusetts and German headquarters will be taking a minimum of one-week furlough or unused vacation. The commercial field team will work on monthly operating plans to allow for flexibility and the potential to increase sequentially each week. These actions are designed to preserve full-time jobs, preserve cash returns and retain the ability to quickly ramp up when demand returns, while at the same time continuing to invest in innovation. These cost actions are intended to last through Q1, but the company will continue to monitor the environment and extend these actions, if necessary.

 

“Everyone at Abiomed would like to express our thanks to the frontline healthcare workers and medical community for all they are doing to support patients and provide much needed medical care. Also, I appreciate our employees who continue to directly support patients 24x7 at hospitals and our headquarters manufacturing, service and shipping teams who continue to come to work to make and ship our Impella heart pumps,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “We will endure the challenges and come

out stronger as Abiomed 2.0 because of the investments in innovation to have products that are smaller, smarter, and more connected in the cloud with AI algorithms for heart recovery.”

 

FISCAL YEAR 2021 OUTLOOK

 

The COVID-19 pandemic has resulted in customers diverting resources to treat COVID-19 patients and deferring cardiac procedures. Due to the uncertain scope and duration of the COVID-19 pandemic and the timing of economic recovery, the company will not be providing full year revenue or operating margin guidance at this time. The company will analyze and monitor this dynamic environment and will provide an update on guidance when appropriate.

 

Due to the current situation on social distancing, we will not be hosting a full investor day in person at our headquarters on May 27th. However, we will be hosting a condensed, virtual investor event focused on our innovation, clinical data and our ECMO acquisition on the same day. Details will be forthcoming.

 

 

EARNINGS CONFERENCE CALL DETAILS

 

The company will host a conference call to discuss the quarterly and full year results at 8:00 a.m. EST on Thursday, April 30, 2020. The conference call will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd A. Trapp, Vice President and Chief Financial Officer.

To listen to the call live, please tune into the webcast via https://edge.media-server.com/mmc/p/gfyn6zsu or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11:00 a.m. EST April 30, 2020 through 11:00 a.m. EST on May 7, 2020. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 7361069.

 

ABOUT ABIOMED

 

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com. Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella 5.5, Impella Connect, and SmartAssist are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella BTR, Impella ECP, CVAD Study, DTU STEMI Study, and Automated Impella Controller are pending trademarks of Abiomed, Inc. 

 

FORWARD-LOOKING STATEMENTS

 

This release contains forward-looking statements, including, without limitation, statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, and future opportunities and expected regulatory approvals. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,”  “will” and other words and terms of similar meaning. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including, without limitation: the scope, scale and duration of the impact of the COVID-19 pandemic, the company’s dependence on Impella® products for all of its revenues; the company’s ability to successfully compete against its existing or potential competitors; the acceptance of the company’s products by cardiac surgeons and interventional cardiologists; long sales and training cycles associated with expansion into new hospital cardiac centers; reduced market acceptance of the company’s products due to lengthy clinician training process; the company’s ability to effectively manage its growth; the company’s ability to successfully commercialize its products; the company’s ability to obtain regulatory approvals and market and sell its products in certain jurisdictions; enforcement actions and product liability suits relating to off-label uses of the company’s products; unsuccessful clinical trials or procedures relating to products under development; the company’s ability to maintain compliance with regulatory requirements; the failure of third-party payers to provide reimbursement of the company’s products; the company’s ability to increase manufacturing capacity to support continued demand for its products; the company or its vendors’ failure to achieve and maintain high manufacturing standards; the failure of the company’s suppliers to provide the components the company requires; the company’s ability to expand its direct sales activities into international markets; the outcome of ongoing securities class action litigation relating to our public disclosures, the company’s ability to integrate acquired companies into its operations and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission (the “SEC”), including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. Unless otherwise required by law, the company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

 

For further information please contact:  

 

Todd Trapp

Tom Langford

Vice President and Chief Financial Officer

Director, Communications & Public Relations

978-646-1680

978-882-8408

ttrapp@abiomed.com

tlangford@abiomed.com

 

 

 

Abiomed, Inc. and Subsidiaries

 

Consolidated Balance Sheets

 

(Unaudited)

 

(in thousands, except share data)

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2020

 

 

March 31, 2019

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

192,341

 

 

$

121,021

 

Short-term marketable securities

 

 

250,775

 

 

 

370,677

 

Accounts receivable

 

 

84,650

 

 

 

90,809

 

Inventories

 

 

90,088

 

 

 

80,942

 

Prepaid expenses and other current assets

 

 

18,009

 

 

 

13,748

 

Total current assets

 

 

635,863

 

 

 

677,197

 

Long-term marketable securities

 

 

207,795

 

 

 

21,718

 

Property and equipment, net

 

 

164,931

 

 

 

145,005

 

Goodwill

 

 

31,969

 

 

 

32,601

 

In-process research and development

 

 

14,913

 

 

 

15,208

 

Long-term deferred tax assets, net

 

 

43,336

 

 

 

77,502

 

Other assets

 

 

117,655

 

 

 

85,115

 

Total assets

 

$

1,216,462

 

 

$

1,054,346

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

32,774

 

 

$

32,185

 

Accrued expenses

 

 

75,107

 

 

 

57,420

 

Deferred revenue

 

 

19,147

 

 

 

16,393

 

Other current liabilities

 

 

4,857

 

 

 

—

 

Total current liabilities

 

 

131,885

 

 

 

105,998

 

Other long-term liabilities

 

 

9,305

 

 

 

1,061

 

Contingent consideration

 

 

9,000

 

 

 

9,575

 

Long-term deferred tax liabilities

 

 

806

 

 

 

822

 

Total liabilities

 

 

150,996

 

 

 

117,456

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Class B Preferred stock, $.01 par value

 

 

—

 

 

 

—

 

Authorized - 1,000,000 shares; Issued and outstanding - none

 

 

 

 

 

 

 

 

Common stock, $.01 par value

 

 

451

 

 

 

451

 

Authorized - 100,000,000 shares; Issued - 47,542,061 shares at March 31, 2020 and 47,026,226 shares at March 31, 2019

 

 

 

 

 

 

 

 

Outstanding - 45,008,687 shares at March 31, 2020 and 45,122,985 shares at March 31, 2019

 

 

 

 

 

 

 

 

Additional paid in capital

 

 

739,133

 

 

 

690,507

 

Retained earnings (accumulated deficit)

 

 

602,482

 

 

 

399,473

 

Treasury stock at cost - 2,533,374 shares at March 31, 2020 and 1,903,241 shares at March 31, 2019

 

 

(265,411

)

 

 

(138,852

)

Accumulated other comprehensive loss

 

 

(11,189

)

 

 

(14,689

)

Total stockholders' equity

 

 

1,065,466

 

 

 

936,890

 

Total liabilities and stockholders' equity

 

$

1,216,462

 

 

$

1,054,346

 

 

 

 

 

Abiomed, Inc. and Subsidiaries

 

Consolidated Statements of Operations

 

(Unaudited)

 

(in thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

Fiscal Years Ended March 31,

 

 

2020

 

2019

 

 

2020

 

2019

 

Revenue

$

 

206,658

 

$

 

207,081

 

 

$

 

840,883

 

$

 

769,432

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

39,369

 

 

 

34,848

 

 

 

 

151,305

 

 

 

129,567

 

Research and development

 

 

25,346

 

 

 

25,548

 

 

 

 

98,759

 

 

 

93,503

 

Selling, general and administrative

 

 

83,891

 

 

 

81,296

 

 

 

 

341,600

 

 

 

321,550

 

 

 

 

148,606

 

 

 

141,692

 

 

 

 

591,664

 

 

 

544,620

 

Income from operations

 

 

58,052

 

 

 

65,389

 

 

 

 

249,219

 

 

 

224,812

 

Other (loss) income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Investment income, net

 

 

3,100

 

 

 

2,769

 

 

 

 

12,167

 

 

 

8,166

 

Other (expense) income, net

 

 

(21,839

)

 

 

30,372

 

 

 

 

(4,561

)

 

 

30,382

 

 

 

 

(18,739

)

 

 

33,141

 

 

 

 

7,606

 

 

 

38,548

 

Income before income taxes

 

 

39,313

 

 

 

98,530

 

 

 

 

256,825

 

 

 

263,360

 

Income tax provision

 

 

7,515

 

 

 

24,569

 

 

 

 

53,816

 

 

 

4,344

 

Net income (A)

$

 

31,798

 

$

 

73,961

 

 

$

 

203,009

 

$

 

259,016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income per share

$

 

0.71

 

$

 

1.64

 

 

$

 

4.49

 

$

 

5.77

 

Basic weighted average shares outstanding

 

 

45,040

 

 

 

45,091

 

 

 

 

45,179

 

 

 

44,911

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted net income per share (B)

$

 

0.70

 

$

 

1.60

 

 

$

 

4.43

 

$

 

5.61

 

Diluted weighted average shares outstanding

 

 

45,575

 

 

 

46,173

 

 

 

 

45,816

 

 

 

46,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(A) Net income includes the effect of the following items:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Excess tax benefits related to stock-based compensation awards

 

 

(1,063

)

 

 

(798

)

 

 

 

(14,838

)

 

 

(69,267

)

Unrealized loss (gain) on investment in Shockwave Medical - net of tax

 

 

13,595

 

 

 

(23,636

)

 

 

 

367

 

 

 

(23,636

)

 

$

 

12,532

 

$

 

(24,434

)

 

$

 

(14,471

)

$

 

(92,903

)

(B) Diluted net income per share includes the effect of the following items:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Excess tax benefits related to stock-based compensation awards

 

 

(0.02

)

 

 

(0.02

)

 

 

 

(0.32

)

 

 

(1.50

)

Unrealized loss (gain) on investment in Shockwave Medical - net of tax

 

 

0.30

 

 

 

(0.51

)

 

 

 

0.01

 

 

 

(0.51

)

 

$

 

0.28

 

$

 

(0.53

)

 

$

 

(0.31

)

$

 

(2.01

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 GRAPHIC 3 g2py4zjfk111000001.jpg GRAPHIC begin 644 g2py4zjfk111000001.jpg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end GRAPHIC 4 gc0yepqxhk3o000001.jpg GRAPHIC begin 644 gc0yepqxhk3o000001.jpg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end EX-101.SCH 5 abmd-20200430.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 abmd-20200430_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 7 abmd-20200430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE JSON 8 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abmd-8k_20200430.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "abmd-8k_20200430.htm" ] }, "labelLink": { "local": [ "abmd-20200430_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "abmd-20200430_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "abmd-20200430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "abmd", "nsuri": "http://www.abiomed.com/20200430", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abmd-8k_20200430.htm", "contextRef": "C_0000815094_20200430_20200430", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abmd-8k_20200430.htm", "contextRef": "C_0000815094_20200430_20200430", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
Apr. 30, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 30, 2020
Entity Registrant Name ABIOMED, Inc.
Entity Central Index Key 0000815094
Entity Emerging Growth Company false
Entity File Number 001-09585
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 04-2743260
Entity Address, Address Line One 22 Cherry Hill Drive
Entity Address, City or Town Danvers
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01923
City Area Code (978)
Local Phone Number 646-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common Stock, $0.01 par value
Trading Symbol ABMD
Name of each exchange on which registered NASDAQ
XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.abiomed.com/20200430/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports abmd-8k_20200430.htm abmd-20200430.xsd abmd-20200430_lab.xml abmd-20200430_pre.xml abmd-ex991_6.htm g2py4zjfk111000001.jpg http://xbrl.sec.gov/dei/2019-01-31 true false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 abmd-8k_20200430_htm.xml IDEA: XBRL DOCUMENT 0000815094 2020-04-30 2020-04-30 false 0000815094 8-K 2020-04-30 ABIOMED, Inc. DE 001-09585 04-2743260 22 Cherry Hill Drive Danvers MA 01923 (978) 646-1400 Common Stock, $0.01 par value ABMD NASDAQ false false false false false XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 16 0001564590-20-019956-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-019956-xbrl.zip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end